Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 13/20 | 0.58 |
| ▸ | TP53 | P04637 | 9/20 | 0.58 |
| ▸ | MAPT | P10636 | 8/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PKLR | P30613 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2611942 | 0.85 | GAA (0.64) | GAATP53MAPTPOLBNR1H4 | |
| SCHEMBL2611927 | 0.79 | GAA (0.57) | GAATP53MAPTPOLBNR1H4 | |
| SCHEMBL2619797 | 0.78 | GAA (0.55) | GAATP53MAPTPOLBNR1H4 | |
| SCHEMBL5166559 | 0.77 | CRHR1 (0.49) | GAATP53MAPTPOLBNR1H4 | |
| SCHEMBL2611937 | 0.76 | GAA (0.55) | GAATP53MAPTPOLBNR1H4 | |
| SCHEMBL2611929 | 0.75 | GAA (0.58) | GAATP53MAPTPOLBSMN1; SMN2 | |
| SCHEMBL1968552 | 0.73 | GAA (0.70) | GAATP53MAPTPOLBNR1H4 | |
| SCHEMBL1691330 | 0.73 | DPP4 (0.50) | GAATP53MAPTNR1H4KDM4E | |
| SCHEMBL2611930 | 0.72 | GAA (0.57) | GAATP53MAPTNR1H4SMN1; SMN2 | |
| SCHEMBL2611913 | 0.72 | ALOX5 (0.65) | GAATP53MAPTNR1H4PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040023972-A1 | Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS | GRUENENTHAL GMBH (DE) | 2004-02-05 | — | — | US | claimed |
| EP-1326613-A1 | USE OF SUBSTITUTED IMIDAZO 1,2-A]PYRIDINE-, IMIDAZO 1,2-A]PYRIMIDINE AND IMIDAZO 1,2-A]PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING NOS-INHIBITING MEDICAMENTS | Grünenthal GmbH (DE) | 2003-07-16 | — | — | EP | claimed |
| WO-2002030428-A1 | USE OF SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE-, IMIDAZO[1,2-A]PYRIMIDINE AND IMIDAZO[1,2-A]PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING NOS-INHIBITING MEDICAMENTS | Grünenthal GmbH (DE) | 2002-04-18 | — | — | WO | claimed |
| EP-1326613-B2 | USE OF SUBSTITUTED IMIDAZO 1,2-A|PYRIDINE-, IMIDAZO ¬1,2-A|PYRIMIDINE AND IMIDAZO ¬1,2-A|PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING NOS-INHIBITING MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2007-04-18 | — | — | EP | disclosed |
| EP-1326613-B1 | USE OF SUBSTITUTED IMIDAZO 1,2-A]PYRIDINE-, IMIDAZO [1,2-A]PYRIMIDINE AND IMIDAZO [1,2-A]PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING NOS-INHIBITING MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2004-06-02 | — | — | EP | disclosed |
| US-20040023972-A1 | Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS | GRUENENTHAL GMBH (DE) | 2004-02-05 | — | — | US | disclosed |
| EP-1326613-A1 | USE OF SUBSTITUTED IMIDAZO 1,2-A]PYRIDINE-, IMIDAZO 1,2-A]PYRIMIDINE AND IMIDAZO 1,2-A]PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING NOS-INHIBITING MEDICAMENTS | Grünenthal GmbH (DE) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002030428-A1 | USE OF SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE-, IMIDAZO[1,2-A]PYRIMIDINE AND IMIDAZO[1,2-A]PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING NOS-INHIBITING MEDICAMENTS | Grünenthal GmbH (DE) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023972-A1 | Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS | NOS1, PTGIS, NOS2 | GAA 536/4885TP53 3796/4885MAPT 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.